Nature Communications (Jul 2019)
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
- Karl E. Carlström,
- Ewoud Ewing,
- Mathias Granqvist,
- Alexandra Gyllenberg,
- Shahin Aeinehband,
- Sara Lind Enoksson,
- Antonio Checa,
- Tejaswi V. S. Badam,
- Jesse Huang,
- David Gomez-Cabrero,
- Mika Gustafsson,
- Faiez Al Nimer,
- Craig E. Wheelock,
- Ingrid Kockum,
- Tomas Olsson,
- Maja Jagodic,
- Fredrik Piehl
Affiliations
- Karl E. Carlström
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Ewoud Ewing
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Mathias Granqvist
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Alexandra Gyllenberg
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Shahin Aeinehband
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Sara Lind Enoksson
- Department of Clinical Immunology Karolinska University Hospital
- Antonio Checa
- Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet
- Tejaswi V. S. Badam
- Department of Bioinformatics, School of Bioscience, University of Skövde
- Jesse Huang
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- David Gomez-Cabrero
- Translational Bioinformatics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Publica de Nevarra (UPNA), IdiSNA
- Mika Gustafsson
- Department of Physics, Chemistry and Biology, Linköping University
- Faiez Al Nimer
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Craig E. Wheelock
- Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet
- Ingrid Kockum
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Tomas Olsson
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Maja Jagodic
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- Fredrik Piehl
- Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet
- DOI
- https://doi.org/10.1038/s41467-019-11139-3
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Dimethyl fumarate (DMF) is an established treatment for relapsing multiple sclerosis with unclear mechanism of action. Here the authors distinguish DMF responders by monocyte counts and redox gene signature in a prospective longitudinal cohort at 3 month of therapy, and associate NOX3 genetic variants with outcome.
